Truist Securities Reiterates CRISPR (CRSP) at Buy, Q4 Results Underscore Continued Execution on Multiple Fronts, "We Are Strong Buyers"
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $220.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
